Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High – Should You Buy?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s stock price reached a new 52-week high on Friday . The stock traded as high as $20.86 and last traded at $20.8490, with a volume of 329078 shares trading hands. The stock had previously closed at $20.25.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Morgan Stanley cut their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. JPMorgan Chase & Co. lowered their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Guggenheim reissued a “buy” rating and set a $21.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Finally, TD Cowen upped their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average price target of $20.33.

Adaptive Biotechnologies Stock Performance

The stock has a market cap of $3.33 billion, a PE ratio of -62.86 and a beta of 2.15. The stock’s 50-day moving average is $15.24 and its two-hundred day moving average is $15.61.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same quarter in the previous year, the company earned ($0.20) earnings per share. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. Analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Insider Activity at Adaptive Biotechnologies

In related news, insider Harlan S. Robins sold 100,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $17.37, for a total transaction of $1,737,000.00. Following the transaction, the insider owned 1,412,058 shares of the company’s stock, valued at $24,527,447.46. This trade represents a 6.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 83,332 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $14.41, for a total value of $1,200,814.12. Following the sale, the chief executive officer directly owned 2,217,781 shares of the company’s stock, valued at approximately $31,958,224.21. This represents a 3.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 551,574 shares of company stock worth $8,427,395. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ADPT. 1492 Capital Management LLC acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth $1,484,000. UBS Group AG increased its stake in Adaptive Biotechnologies by 101.6% in the 4th quarter. UBS Group AG now owns 511,927 shares of the company’s stock valued at $8,314,000 after buying an additional 257,947 shares during the period. Jupiter Asset Management Ltd. increased its stake in Adaptive Biotechnologies by 33.8% in the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock valued at $5,892,000 after buying an additional 91,683 shares during the period. Rhenman & Partners Asset Management AB raised its position in Adaptive Biotechnologies by 22.2% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after buying an additional 110,000 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Adaptive Biotechnologies by 103.9% during the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after buying an additional 1,363,181 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.